OCT 11, 2018 7:30 AM PDT

Keynote Presentation: In Advanced Cancers Curative Therapies Must Target All Cancer Cells

Speaker
  • Program Director, National Science Foundation
    Biography
      Dr. Blagoev completed his first MS degree in Nuclear and Elementary Particle Physics at Sofia University in 1990 and a second MS degree at the Physics Department at Florida Atlantic University in 1992. He received a PhD from the Physics Department at Boston College in 1998 and continued his research on superconductivity and magnetism at University of Cambridge as a postdoctoral fellow. In 1999 he moved to Harvard University Medical School working on mathematical models of ultrasound propagation in the brain. In 2002 he joined the Theoretical Division of Los Alamos National Laboratory as a staff member working on condensed matter physics as well as mathematical models of telomere dynamics and its influence on aging and cancer. Dr. Blagoev moved to the National Science Foundation as a Program Director in the Division of Physics in 2007, where he currently directs the Physics of Living Systems program. Since 2015 he is an Associate Research Scientist at the Department of Biophysics at Johns Hopkins University. His research interests focus on understanding the mechanisms of tumor growth during cancer progression and analysis of cancer clinical trials. He is also interested in the non-equilibrium phyical processes in mammalian cells and their role in DNA repair.

    Abstract

    In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expression of stem cell markers have been shown to proliferate when grafted in animals and have been called cancer stem cells in analogy to adult stem cells maintaining organ homeostasis. In this talk different kinetic models of tumor proliferation are presented and compared to tumor kinetics in large number of patients with metastatic disease obtained from cancer clinical trials. The conclusion from this analysis is that almost all analyzed tumors after initial volume decrease begin to grow exponentially, inconsistent with the hypothesis that small number of self-renewing, drug resistance cells drive this growth. Cell proliferation resembles the proliferation of embryonic stem cells early in embryogenesis and not of adult stem cells. Our data is consistent with exponential cell proliferation with fixed growth rate, implying that the number of proliferating cells in these cancers is very large and divide symmetrically. The main implication of this work is that cancer therapies must target all cells and not just a small subset of cells in a tumor. 

    Learning Objectives: 

    1. To present current models of tumor growth and evidence that in advanced cancers, although rare stem-like cancer cells might exist, the majority of cells drive tumor growth.
    2. For a therapy to be curative it has to target all cancer cells, because most cells are the source of drug resistance. 


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    OCT 11, 2018 7:30 AM PDT

    Keynote Presentation: In Advanced Cancers Curative Therapies Must Target All Cancer Cells


    Specialty

    Cancer Diagnostics

    Cancer

    Cancer Research

    Bioinformatics

    Gene Expression

    Research And Development

    Mass Cytometry

    Biology

    Clinical Diagnostics

    T-Cells

    Lab Safety

    Biomarkers

    Immunotherapeutics

    Pcr/rt-Pcr/real-Time Pcr

    Cell

    Geography

    North America60%

    Asia20%

    Europe20%

    Registration Source

    Website Visitors100%

    Job Title

    Research Scientist50%

    Student25%

    Medical Laboratory Technician25%

    Organization

    Academic Institution20%

    Government20%

    Manufacturer - Other20%

    Contract Research Organization (Cro)20%

    Other20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more